|
Finally got around to this. UN-official, of course
|
8
|
Resverlogix Corp.
|
Sep 16, 2015 06:23PM
|
|
Re: Thoughts?
|
7
|
Resverlogix Corp.
|
Apr 08, 2021 12:58AM
|
|
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
|
7
|
Resverlogix Corp.
|
Jan 24, 2018 07:23PM
|
|
A Belated Thankyou
|
7
|
Resverlogix Corp.
|
Sep 30, 2019 12:27AM
|
|
Article Inflammation & CVD
|
7
|
Resverlogix Corp.
|
Jun 17, 2022 01:03PM
|
|
BETonMACE Prespecified Cognition Assessment Results - Post-CTAD Conference Call - Transcript - 191206
|
7
|
Resverlogix Corp.
|
Dec 08, 2019 10:12AM
|
|
Covid and BETonMACE, etc. Rambling.
|
7
|
Resverlogix Corp.
|
Apr 24, 2021 03:25AM
|
|
Drug Discovery Targeting BRD4
|
7
|
Resverlogix Corp.
|
Oct 04, 2017 02:23PM
|
|
Safety Data Announcement - positive
|
7
|
Resverlogix Corp.
|
Aug 11, 2016 07:15AM
|
|
Two articles - Apabetalone for Colon Cancer?
|
7
|
Resverlogix Corp.
|
Jul 09, 2021 05:35AM
|
|
RVX 2019_11_18 Webcast - Detailed Preliminary Results of BETonMACE - Transcript
|
7
|
Resverlogix Corp.
|
Nov 19, 2019 07:22AM
|
|
Re: Wolf - A Short Summary of Statements on Partnership Discussions since 2016
|
7
|
Resverlogix Corp.
|
Sep 20, 2020 03:31AM
|
|
Re: RVX 2019_11_18 Webcast - Detailed Preliminary Results of BETonMACE - Transcript
|
7
|
Resverlogix Corp.
|
Nov 19, 2019 08:21AM
|
|
Re: Don's latest presentation
|
7
|
Resverlogix Corp.
|
Sep 22, 2020 08:12PM
|
|
Article
|
7
|
Resverlogix Corp.
|
Mar 14, 2022 06:36PM
|
|
Pharmacological Modulation of BET Family in Sepsis
|
7
|
Resverlogix Corp.
|
Mar 11, 2021 02:27AM
|
|
Anybody ever post this link already?
|
7
|
Resverlogix Corp.
|
Apr 14, 2023 04:34AM
|
|
Re: The synergy of rosuvastatin (Crestor) with apabetalone
|
7
|
Resverlogix Corp.
|
Oct 07, 2019 08:17AM
|
|
Re: Repetitive musings on repetitive issues
|
6
|
Resverlogix Corp.
|
Feb 12, 2021 05:04PM
|
|
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study (BRD4i)
|
6
|
Resverlogix Corp.
|
Sep 21, 2018 04:03AM
|
